Also trades as: ATX.AX (ASX) · $vol 0M
INNMF OTC
Amplia Therapeutics Limited
1W: -13.0%
1M: -11.1%
3M: -30.4%
YTD: -25.8%
1Y: -20.0%
3Y: +61.6%
5Y: -48.7%
$0.08
-0.01 (-5.88%)
Weekly Expected Move ±12.6%
$0
$0
$0
$0
$0
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
-100.0% ▼
Gross Profit
-$92K
-102.6% ▼
Operating Income
-$13M
-102.7% ▼
Net Income
-$8M
-17.5% ▼
EPS (Diluted)
$-0.02
+23.4% ▲
EBITDA
-$13M
-93.3% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $2M | $1M | $4M | $4M | $0 |
| YoY Growth | +29.3% | -40.0% | +274.3% | -15.0% | -100.0% |
| Cost of Revenue | $3K | $73K | $442K | $211K | $92K |
| Gross Profit | $2M | $1M | $4M | $4M | -$92K |
| Gross Margin | 99.8% | 93.8% | 90.1% | 94.4% | — |
| R&D Expenses | $4M | $5M | $6M | $8M | $9M |
| SG&A Expenses | $2M | $3M | $3M | $3M | $4M |
| Operating Expenses | $6M | $7M | $8M | $10M | $13M |
| Operating Income | -$4M | -$6M | -$4M | -$7M | -$13M |
| Operating Margin | -183.7% | -520.3% | -99.4% | -172.2% | — |
| Interest Expense | $1K | $54K | $78K | $0 | $17K |
| Income Before Tax | -$4M | -$6M | -$9M | -$7M | -$13M |
| Tax Expense | $0 | $0 | -$4M | $0 | -$5M |
| Net Income | -$4M | -$6M | -$5M | -$7M | -$8M |
| Net Margin | -183.7% | -524.8% | -101.1% | -173.7% | — |
| EPS (Diluted) | $-0.03 | $-0.03 | $-0.02 | $-0.02 | $-0.02 |
| EBITDA | -$4M | -$7M | -$5M | -$7M | -$13M |
| Shares Outstanding | 146M | 194M | 194M | 307M | 470M |